Your browser is no longer supported. Please, upgrade your browser.
Decibel Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.49 Insider Own0.10% Shs Outstand24.88M Perf Week-1.50%
Market Cap116.08M Forward P/E- EPS next Y-1.89 Insider Trans-20.25% Shs Float11.18M Perf Month-15.47%
Income0.60M PEG- EPS next Q-0.47 Inst Own69.60% Short Float2.81% Perf Quarter-37.80%
Sales- P/S- EPS this Y113.20% Inst Trans0.20% Short Ratio4.83 Perf Half Y-35.26%
Book/sh6.20 P/B0.74 EPS next Y26.60% ROA0.40% Target Price22.17 Perf Year-
Cash/sh5.69 P/C0.81 EPS next 5Y- ROE0.50% 52W Range4.28 - 24.39 Perf YTD-1.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.18% Beta-
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low7.24% ATR0.33
Employees40 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)40.43 Volatility4.68% 6.44%
OptionableYes Debt/Eq0.00 EPS Q/Q54.00% Profit Margin- Rel Volume1.15 Prev Close4.66
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume65.05K Price4.59
Recom1.60 SMA20-1.98% SMA50-20.97% SMA200-38.81% Volume74,669 Change-1.50%
Nov-15-21Initiated H.C. Wainwright Buy $23
Oct-22-21Initiated Robert W. Baird Outperform $21
Mar-09-21Initiated SVB Leerink Outperform $26
Mar-09-21Initiated Citigroup Buy $29
Mar-09-21Initiated BMO Capital Markets Outperform $30
Mar-09-21Initiated Barclays Overweight $30
Jan-04-22 07:00AM  
Dec-06-21 07:30AM  
Dec-01-21 05:00AM  
Nov-24-21 10:07AM  
Nov-22-21 07:30AM  
Nov-10-21 07:30AM  
Nov-08-21 07:00AM  
Oct-28-21 10:24AM  
Oct-20-21 07:30AM  
Oct-14-21 06:30AM  
Sep-30-21 05:42PM  
Sep-09-21 11:25AM  
Sep-02-21 07:30AM  
Aug-18-21 07:30AM  
Aug-10-21 07:30AM  
Jun-02-21 08:30AM  
May-24-21 04:15PM  
May-19-21 08:00AM  
May-13-21 05:05PM  
May-12-21 01:57AM  
Apr-28-21 08:00AM  
Apr-08-21 08:00AM  
Mar-29-21 04:05PM  
Mar-22-21 08:00AM  
Mar-05-21 08:46PM  
Mar-04-21 08:00AM  
Feb-24-21 07:00AM  
Feb-19-21 07:00AM  
Feb-12-21 05:05PM  
Feb-11-21 09:51PM  
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trask AnnaSee RemarksJan 03Sale5.033781,9011,864Jan 04 04:12 PM
Trask AnnaSee RemarksDec 02Sale6.375,29133,6882,242Dec 06 04:20 PM
Trask AnnaSee RemarksNov 03Sale8.343783,1527,533Nov 04 08:00 AM
Trask AnnaSEE REMARKSNov 02Sale8.314,91340,8277,911Nov 03 04:16 PM
Trask AnnaSee RemarksOct 14Sale7.555,36440,48112,824Oct 15 04:57 PM
Reid LaurencePresident and Chief ExecutiveSep 15Buy7.6410,00076,40025,849Sep 17 09:48 PM
GLAXOSMITHKLINE PLCDirectorFeb 17Buy18.00150,0002,700,0001,183,663Feb 19 04:50 PM
ORBIMED ADVISORS LLCDirectorFeb 17Buy18.001,666,66629,999,9883,843,206Feb 19 07:09 PM
Foy MatthewDirectorFeb 17Buy18.00150,0002,700,0001,183,663Feb 19 06:59 PM
Casdin Partners Master Fund, L10% OwnerFeb 17Buy18.00575,00010,350,0001,121,421Feb 19 06:56 PM
Thompson Peter A.DirectorFeb 17Buy18.001,666,66629,999,9883,843,206Feb 19 06:50 PM